Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD

Chest

Volumn 144, Issue 2, 2013, Pages 498-506

  Dransfield, Mark T ^a,c,d   Wilhelm, Andrew M ^a,c   Flanagan, Brian ^a   Courville, Clifford ^a   Tidwell, Sherry L ^a,c,d   Raju, S Vamsee ^a,c,d   Gaggar, Amit ^a,c,d   Steele, Chad ^a,c,d   Tang, Li Ping ^a,d   Liu, Bo ^a,d   Rowe, Steven M ^a,b,c,d  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADULT; AGED; ARTICLE; BRONCHUS BIOPSY; CHLORIDE CONDUCTANCE; CHLORIDE TRANSPORT; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPNEA; FEMALE; HUMAN; HUMAN TISSUE; LOWER RESPIRATORY TRACT; MALE; PATHOGENESIS; POTENTIAL DIFFERENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMOKING;

EID: 84881494429     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-0274     Document Type: Article

References (37)

1. National Heart, Lung, and Blood Institute, National Institutes of Health. Morbidity and Mortality: 2007 Chart Book on Cardiovascular, Lung and Blood Diseases. Bethesda, MD: National Institutes of Health; 2007:17.
2. Centers for Disease Control and Prevention; National Center for Health Statistics. Deaths: fi nal data for 2007. Final Vital Stat Rep. 2010 ;58(19).
3. Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med. 2007; 176 (5): 454-459.
4. Hogg JC, Chu F, Utokaparch S, et al. The nature of smallairway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350 (26): 2645-2653.
5. Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med. 2010; 363 (23): 2233-2247.
6. Rowe SM, Miller S, Sorscher EJ. Cystic fi brosis. N Engl J Med. 2005; 352 (19): 1992-2001.
7. Sethi S, Maloney J, Grove L, Wrona C, Berenson CS. Airway infl ammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 173 (9): 991-998.
8. Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A. Airway infl ammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J. 1999; 14 (5): 1015-1022.
9. Martínez-García MA, Soler-Cataluña JJ, Donat Sanz Y, et al. Factors associated with bronchiectasis in patients with COPD. Chest. 2011; 140 (5): 1130-1137.
10. Knowles MR, Durie PR. What is cystic fi brosis? N Engl J Med. 2002; 347 (6): 439-442.
11. Ramsey BW, Davies J, McElvaney NG, et al; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fi brosis and the G551D mutation. N Engl J Med. 2011; 365 (18): 1663-1672.
12. Cantin AM, Hanrahan JW, Bilodeau G, et al. Cystic fi brosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med. 2006; 173 (10): 1139-1144.
13. Kreindler JL, Jackson AD, Kemp PA, Bridges RJ, Danahay H. Inhibition of chloride secretion in human bronchial epithelial cells by cigarette smoke extract. Am J Physiol Lung Cell Mol Physiol. 2005; 288 (5): L894-L902.
14. Savitski AN, Mesaros C, Blair IA, Cohen NA, Kreindler JL. Secondhand smoke inhibits both Cl-and K 1 conductances in normal human bronchial epithelial cells. Respir Res. 2009; 10: 120.
15. Sloane PA, Shastry S, Wilhelm A, et al. A pharmacologic approach to acquired cystic fi brosis transmembrane conductance regulator dysfunction in smoking related lung disease. PLoS ONE. 2012; 7 (6): e39809.
16. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med. 1999; 159 (1): 179-187.
17. ATS Committee on Profi ciency Standards for Clinical Pulmo nary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166 (1): 111-117.
18. Brooks SM. The evaluation of occupational airways disease in the laboratory and workplace. J Allergy Clin Immunol. 1982; 70 (1): 56-66.
19. Leidy NK, Schmier JK, Jones MK, et al. Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale. Respiratory Med. 2003 ;97(suppl A):S59-S70.
20. Solomon GM, Konstan MW, Wilschanski M, et al. An international randomized multicenter comparison of nasal potential difference techniques. Chest. 2010; 138 (4): 919-928.
21. Rowe SM, Clancy JP, Wilschanski M. Nasal potential difference measurements to assess CFTR ion channel activity. Methods Mol Biol. 2011; 741: 69-86.
22. Davies JC, Davies M, McShane D, et al. Potential difference measurements in the lower airway of children with and without cystic fi brosis. Am J Respir Crit Care Med. 2005; 171 (9): 1015-1019.
23. Rowe SM, Varga K, Rab A, et al. Restoration of W1282X CFTR activity by enhanced expression. Am J Respir Cell Mol Biol. 2007; 37 (3): 347-356.
24. Varga K, Goldstein RF, Jurkuvenaite A, et al. Enhanced cell surface-stability of rescued DeltaF508 cystic fi brosis transmembrane conductance regulator by pharmacological chaperones. Biochem J. 2008; 410 (3): 555-564.
25. Pyle LC, Fulton JC, Sloane PA, et al. Activation of cystic fi brosis transmembrane conductance regulator by the fl avonoid quercetin: potential use as a biomarker of D F508 cystic fi brosis transmembrane conductance regulator rescue. Am J Respir Cell Mol Biol. 2010; 43 (5): 607-616.
26. Bonfield TL, Panuska JR, Konstan MW, et al. Infl ammatory cytokines in cystic fi brosis lungs. Am J Respir Crit Care Med. 1995; 152 (6 pt 1): 2111-2118.
27. Clunes LA, Davies CM, Coakley RD, et al. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. FASEB J. 2012;26(2): 533-545.
28. Friedlander AL, Lynch D, Dyar LA, Bowler RP. Phenotypes of chronic obstructive pulmonary disease. COPD. 2007; 4 (4): 355-384.
29. Rennard SI, Vestbo J. The many "small COPDs": COPD should be an orphan disease. Chest. 2008; 134 (3): 623-627.
30. Han MK, Kazerooni EA, Lynch DA, et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene Study: associated radiologic phenotypes. Radiology. 2011 ;261(1): 274-282.
31. Koblizek V, Tomsova M, Cermakova E, et al. Impairment of nasal mucociliary clearance in former smokers with stable chronic obstructive pulmonary disease relates to the presence of a chronic bronchitis phenotype. Rhinology. 2011; 49 (4): 397-406.
32. Retamales I, Elliott WM, Meshi B, et al. Amplifi cation of infl ammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med. 2001; 164 (3): 469-473.
33. Le Gars M, Descamps D, Roussel D, et al. Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. Am J Respir Crit Care Med. 2013; 187(2): 170-179.
34. Guimbellot JS, Fortenberry JA, Siegal GP, et al. Role of oxygen availability in CFTR expression and function. Am J Respir Cell Mol Biol. 2008; 39 (5): 514-521.
35. Bartoszewski R, Rab A, Twitty G, et al. The mechanism of cystic fi brosis transmembrane conductance regulator transcriptional repression during the unfolded protein response. J Biol Chem. 2008; 283 (18): 12154-12165.
36. Kim V, Han MK, Vance GB, et al; COPDGene Investigators. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011; 140 (3): 626-633.
37. Knowles MR, Buntin WH, Bromberg PA, Gatzy JT, Boucher RC. Measurements of transepithelial electric potential differences in the trachea and bronchi of human subjects in vivo. Am Rev Respir Dis. 1982; 126 (1): 108-112.